Bernstein has downgraded Amgen (AMGN) to Market Perform from Outperform, arguing that 2026 could be a “waiting year” for the ...

Investing in dividend stocks, which can help boost returns through dividend reinvestment, is particularly good, as they have ...

Coverage of a new PCSK9 trial makes bold claims about prevention and risk reduction. But how well do they hold up to scrutiny ...

After a flurry of Big Pharma deals in the first week of the new year, the life sciences industry is heading to San Francisco ...

Chief Executive Officer Bob Bradway told attendees at a J.P. Morgan-hosted event that the company views 2026 as a ...

Currently available therapies such as niacin and PCSK9 inhibitors such as Repatha (evolocumab) and Praluent (alirocumab) can reduce Lp (a) levels, but their impact is modest. Another challenge in ...

The deals tout significant discounts for people who pay out of pocket for certain medications. But most people with insurance ...

Amgen has announced a deal with the US government that will lower the company’s prescription drug costs for US patients while reinforcing its commitment to US innovation.

The drug manufacturing giant is expected to announce its fiscal fourth-quarter earnings for 2025 in the near term. Ahead of the event, analysts expect AMGN to report a profit of $4.74 per share on a ...

From a price-performance perspective, BMY has fetched slightly better returns than AMGN in the past six months. Shares of AMGN have gained 13.5%, while those of BMY have gained 13.9%. The industry has ...